Expression of Spred1 and/or Spred2 was frequently reduced in hepatocellular carcinoma and prostate cancer [15, 16], while decreased Spred levels were associated with increased tumor invasion and metastasis [16, 17]. This evidence concerns the gene SPRED2 and prostate cancer.